STING1 and neoplasm: Interestingly, in our study, we observed the relapse of subcutaneous MC38 tumors after 3 doses of STING monotherapy, while iBINP treatment exhibited enhanced in vivo efficacy in driving tumor regression and inducing durable, tumor-specific immune memory.